Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CMTR-CHEMTRAK FDA OK -- Ignore unavailable to you. Want to Upgrade?

To: Lance who wrote (1053)	6/10/1998 3:25:00 PM
From: Michael Thayres	Read Replies (1) \| Respond to of 1172

CMTR NEWS (COMTEX) ChemTrak Signs Contract Research Pact With Pfizer Inc. ChemTrak Signs Contract Research Pact With Pfizer Inc. SUNNYVALE, CALIF. (June 10) BUSINESS WIRE -June 10, 1998--ChemTrak Inc. (Nasdaq:CMTR) Wednesday announced that it has signed an agreement with Pfizer Inc. of New York (NYSE:PFE) to develop a disposable, quantitative, fingerstick whole blood test for one of Pfizer's drugs in development using ChemTrak's patented AccuMeter technology. As part of the agreement, Pfizer will pay ChemTrak approximately $400, 000 in quarterly installments over the next 18 months to develop the test. Pending successful clinical trials of the Pfizer drug, ChemTrak will remain the exclusive manufacturer of the AccuMeter Test. ChemTrak's proprietary AccuMeter platform is covered by 15 active patents and has four patents pending. Its technology is the foundation of three ChemTrak products; the CholesTrak Home Cholesterol Test, available at drug and mass merchandiser outlets, that allows consumers to monitor their progress while on a cholesterol lowering program; the AccuMeter H. pylori Test, used to detect the presence of antibodies to the bacterium associated with ulcers; and the ChemTrak AccuMeter Theophylline Test, recently cleared by the FDA, to monitor the concentration of the asthma drug Theophylline in blood. The technology is easily adaptable to monitor therapeutic drugs. "We are extremely pleased Pfizer has chosen ChemTrak to develop a test for their drug," said Edward F. Covell, President and Chief Executive. "We have been systematically streamlining and restructuring our R & D department to reflect our increased dedication to becoming a consumer-oriented marketing company. This has enabled us to focus our resources on the most innovative and productive R & D projects," he continued. "Securing this new fully funded R & D project illustrates Pfizer's faith in the ease of use and dependability of our AccuMeter platform and it represents an excellent opportunity to become an OEM (Original Equipment Manufacturer) for Pfizer in addition to marketing our current product line," Covell said. ChemTrak's has a wide range of products for home use, which are available at all major chain drug and mass merchant outlets. ChemTrak's most recent addition to its over-the-counter line is the Parent's Alert Home Drug Test Service, a counselor supported home drug test service committed to helping parents prevent and eliminate drug abuse by their children. The CholesTrak Home Cholesterol Test, and the ColoCARE Home Test to Detect the Early Warning Signs of Colorectal Disease are both designed to help consumers take a more proactive role in their personal healthcare. Located in Sunnyvale, ChemTrak is a medical diagnostics company offering reliable and easy-to-use medical testing systems for in-home use and use in doctors' offices. ChemTrak medical tests are designed to screen and diagnose health conditions with accuracy comparable to laboratory tests. The statements in this release regarding products and revenues are forward looking and subject to risk and uncertainty, and future results could differ materially from past performance. For a detailed discussion of factors that may affect the company's operating results, interested parties should review the company's Securities and Exchange Commission reports, including the ChemTrak Form 10-Q for the quarter ended March 31, 1998, as well as the Annual Report on Form 10-K for the year ended Dec. 31, 1997, filed with the SEC. -0- MCB/la* MT/la CONTACT: ChemTrak Inc., Sunnyvale, Calif. Donald V. Fluken, 408/773-8156 or Self & Associates Trudy M. Self, 818/880-5437 KEYWORD: CALIFORNIA INDUSTRY KEYWORD: MEDICINE PRODUCT KEY: CHTRFX Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com * end of story *